Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Rapid symptomatic relief is an important treatment goal for patients with ulcerative colitis (UC). We aimed to characterize early response with ustekinumab in patients with moderate-to-severe UC during the initial 16 weeks of treatment.
Methods: We performed a post hoc analysis of data from A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis trial. Patients (N = 961) were randomized (1:1:1) to receive intravenous 130 mg ustekinumab, approximately 6 mg/kg ustekinumab, or placebo at week 0. Symptomatic remission, absolute stool number, Mayo stool frequency and rectal bleeding subscores, partial Mayo score, C-reactive protein, and fecal calprotectin were assessed in the overall population and for patients in the biologic-naïve or prior biologic failure subgroups.
Results: A significantly greater percentage of patients in the 130-mg ustekinumab (20.0%; P = .015) or approximately 6-mg/kg ustekinumab (20.2%; P = .012) groups achieved symptomatic remission at week 2 vs placebo (12.9%). Mean [SD] changes from baseline in daily stool number on day 7 were greater in the ustekinumab groups (-1.1 [2.6] in 130 mg [P = .065] and -1.2 [2.5] in ∼6 mg/kg [P = .017]) vs placebo (-0.7 [2.7]). The percentage of patients with Mayo stool frequency subscore of 1 or less and rectal bleeding subscore of 0 increased from baseline through week 16 for both ustekinumab groups. Significant improvements in partial Mayo scores were observed by week 2 in both ustekinumab groups vs placebo (P ≤ .001). Significantly more patients in the ustekinumab groups had normalized C-reactive protein levels from week 2 to week 8 vs placebo (P ≤ .05). Similar results were observed with normalized fecal calprotectin levels between week 2 and week 4 (P ≤ .05).
Conclusions: Ustekinumab improved symptoms in patients with UC compared with placebo in as early as 7 days, indicating rapid onset of effect after induction.
Clinical Trial Registry Number: ClinicalTrials.gov: NCT02407236.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2022.02.050 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.
Pharmacoeconomics
August 2025
Department of Gastroenterology, Rijnstate Hospital, Arnhem, The Netherlands.
Objectives: The clinical pathway for patients with moderate-to-severe Crohn's disease (CD) typically includes sequential pharmacologic treatment as well as surgery, but positioning of different therapies within these sequences remains challenging. Cost-utility analysis rarely captures these sequences and does not incorporate registry data on long-term effectiveness. In this study, we aim to overcome these limitations.
View Article and Find Full Text PDFReal-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study.
Clin Gastroenterol Hepatol
August 2025
Department of gastroenterology, CHU Amiens-Picardie, Université de Picardie Jules Verne, Unité Peritox, France.
Background And Aims: We compared the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent.
Methods: In this multicenter real-world evidence study, we consecutively included UC patients ≥18 years-old, previously exposed to anti-TNF therapy, with partial Mayo score >2 and, starting tofacitinib or ustekinumab. All the comparisons were performed using propensity score analyses.
Comparative Effectiveness of Ustekinumab and Vedolizumab as Maintenance Therapy After Tacrolimus-Induced Improvement in Patients with Acute Severe Ulcerative Colitis: A Retrospective Cohort Study.
J Clin Med
August 2025
Department of Gastroenterology, School of Medicine, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Hyogo, Japan.
Acute severe ulcerative colitis (ASUC) is often managed by tacrolimus induction therapy followed by maintenance therapy. We compared the effectiveness of ustekinumab versus vedolizumab as maintenance therapies after tacrolimus induced improvement in patients with ASUC. This single-center retrospective cohort study included patients with ASUC who received tacrolimus induction therapy followed by ustekinumab or vedolizumab between January 2018 and November 2024.
View Article and Find Full Text PDFA systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.
Inflammopharmacology
August 2025
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background: Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.
View Article and Find Full Text PDFA Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52).
J Am Acad Dermatol
August 2025
Department of Dermatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Electronic address:
Background: BAT2206 is being developed as a ustekinumab (UST) biosimilar.
Objectives: Equivalent efficacy and comparable safety results of BAT2206 and UST in patients with moderate-to-severe psoriasis up to Week 28 (treatment period [TP] 1) have been reported previously. TP2 (post Week 28 to 52) results are presented here.